Henkle E, et al. - In a cohort of U.S. Medicare enrollees with a bronchiectasis diagnosis (494.0/494.1) between 2006 and 2014, researchers compared chronic users of inhaled corticosteroids (ICS) vs macrolide monotherapy with respect to risks of respiratory infections. They excluded cases of cystic fibrosis. They used standardised mean differences to compare the features of the exposure cohorts. To account for treatment differences, a propensity score was calculated. An increased risk of hospitalised respiratory infections was observed in relation to the use of ICS vs macrolide monotherapy among patients with bronchiectasis.